Family 2. Modified hygromycin B resistance-conferring gene
This family of patents is directed to modified DNA sequences of the hpt gene. The modified hpt gene is useful for cloning, isolating and characterizing promoters and also for constructing gene fusions that act as dominant selectable markers in appropriate host cells.
Differences to the wild-type sequence of the gene lie in the removal of the first, first and second, or first, second and third codons in the amino (N-) terminus of the HPT enzyme.
Plasmids bearing such truncated versions of the hpt gene are also part of the claimed invention. The plasmids also comprise non-native prokaryotic and eukaryotic transcriptional and translational activator sequences.
In addition, the Canadian and the United States patents claim the amino acid sequence of a modified HPT enzyme.
E. coli and Saccharomyces cerevisiae transformants with the vectors of the invention are also claimed in the Australian patent.
The disclosed modified sequence corresponds to the structural sequence of the hpt gene contained in the 1.45 kb restriction fragment of the pKC222 plasmid, except for the first N-terminal amino acids and the stop codon at the C-terminus, which are variable.
|
Patents members of Family 2 |
|||
| Country | Granted Patent No. | Filing date | Issue date |
|---|---|---|---|
|
Australia |
AU 565625 B2 |
July 20, 1984 |
September 24, 1987 |
|
Canada |
CA 1278540 A1 |
July 16, 1984 |
January 2, 1991* |
|
Europe** |
July 17, 1984 |
March 14, 1990 |
|
|
Hungary |
HU 200366 B |
July 20, 1984 |
May 28, 1990 |
|
Ireland |
IE 9357776 B |
July 17, 1984 |
April 7, 1993 |
|
United States |
May 31, 1988 |
October 2, 1990** |
|
|
* Patent term of the Canadian and United States patents is 17 years from the date of issuance. **The European patent was converted to a national patent in Austria (AT), Belgium (BE), France (FR), Germany (DE), Italy (IT); Liechtenstein (LI); Luxemburg (LU); Netherlands (NL), Sweden (SE) and Switzerland (CH). There are related patent applications pending in Denmark, Finland, Greece, Israel, and Japan. |
|||
The modified hygromycin phosphotransferase sequence is inserted into a plasmid either alone or with a transcriptional and translational activator sequence. In the examples given, the inventors used bacterial sequences such as the coding sequence for the first 12 amino acids of the E. coli lacZ gene and eukaryotic sequences such as the yeast heat shock genes YG101 and YG100 and the phosphoglycerate kinase gene (PGK) as transcriptional and translational activator sequences.
The inventors state that other synthesized sequences encoding the same amino acids as those encoded by the disclosed sequence are within the scope of the invention.
The information contained in this page was believed to be correct at the time it was collated. New patents and patent applications, altered status of patents, and case law may have resulted in changes in the landscape. CAMBIA makes no warranty that it is correct or up to date at this time and accepts no liability for any use that might be made of it. Corrections or updates to the information are welcome. Please send an email to info@bios.net.
There are no comments.